Pharmacy Podcast Network

By Pharmacy Podcast NetworkNews Medicine Health & Fitness Education Business News

Favorites
83
Followers
Typical duration
44 min
per episode

Based on Podcast App listening data

Pharmacy Podcast Network episodes

December 08, 2020 Trusting your Pharmacist, Patient's Safety, & Prescription Packaging | RxSafe Podcast Series
These days, your patients may be wondering, "How many people touch these pills before I take them?!" COVID-19 has increased pressure on healthcare providers to consider the use of “touchless technology” and other best practices to reduce disease transmission and keep patients safe.
This podcast episode will discuss consumer demand for 'no contact' medication packaging, and how you can differentiate your pharmacy and increase customer loyalty by providing safe, accurate, and untouched prescriptions.
As compliance packaging becomes increasingly popular, pharmacy owners are starting to look at dispensing costs -- not in terms of drug wholesale costs, rebates and DIR fees -- but in terms of vials versus blisters, or vials versus pouches.
After all, reimbursement doesn't change based on the packaging. The patients are prescribed the same NDCs, and their copay is the same regardless of whether the drugs go into a little amber bottle, a 7-day blister pack, or a strip of pouches labeled, ‘morning,’ ‘afternoon,’ and ‘evening.’
But what about your pharmacy costs, and specifically your dispensing costs -- including labor and materials -- for getting the scripts into the patients’ hands?
Regular readers of our blog may remember we already conducted a deep dive into the cost of strip packaging consumables last year. Consumable costs for our RapidPakRx™ strip packaging system are demonstrably lower than competing systems.
Special Guests:
Joe Williams, Brisson Pharmacy
Roberta Vining, Riley's Drugs
See omnystudio.com/listener for privacy information.
39 min
December 08, 2020 I Shrunk the Pandemic! | GameChangers
In the never ending battle with COVID-19, new studies have demonstrated a role for IVIG in the treatment of acute COVID-19 pneumonia, the potential benefit of honey and black seed in mild to moderate COVID-19, and the efficacy of an mRNA vaccine. What does this all mean for current practice?
Additional References:
IVIG: Gharebaghi, N., Nejadrahim, R., Mousavi, S.J. et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 20, 786 (2020). https://doi.org/10.1186/s12879-020-05507-4
Honey: Ashraf S, Ashraf S, Imran M, et al. Efficacy of honey and Nigella sativa against COVID-19: HNS-COVID-PK Trial. medRxiv 2020.10.30.20217364; doi: https://doi.org/10.1101/2020.10.30.20217364
Cleveland Clinic Hospitalization Risk for COVID-19 Positive Calculator: https://riskcalc.org/COVID19Hospitalization/
Cleveland Clinic Predict COVID-19 test result Calculator: https://riskcalc.org/COVID19/
This episode is accredited for CPE. Subscribe at CEimpact https://www.ceimpact.com/pharmacist and claim your CE today!
The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
27 min
December 08, 2020 I Shrunk the Pandemic! | GameChangers
In the never ending battle with COVID-19, new studies have demonstrated a role for IVIG in the treatment of acute COVID-19 pneumonia, the potential benefit of honey and black seed in mild to moderate COVID-19, and the efficacy of an mRNA vaccine. What does this all mean for current practice?
Additional References:
IVIG: Gharebaghi, N., Nejadrahim, R., Mousavi, S.J. et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 20, 786 (2020). https://doi.org/10.1186/s12879-020-05507-4
Honey: Ashraf S, Ashraf S, Imran M, et al. Efficacy of honey and Nigella sativa against COVID-19: HNS-COVID-PK Trial. medRxiv 2020.10.30.20217364; doi: https://doi.org/10.1101/2020.10.30.20217364
Cleveland Clinic Hospitalization Risk for COVID-19 Positive Calculator: https://riskcalc.org/COVID19Hospitalization/
Cleveland Clinic Predict COVID-19 test result Calculator: https://riskcalc.org/COVID19/
This episode is accredited for CPE. Subscribe at CEimpact https://www.ceimpact.com/pharmacist and claim your CE today!
The CE for this episode is supported by an educational grant from Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections.
See omnystudio.com/listener for privacy information.
27 min
December 08, 2020 Changing of the Guard | Beyond the Sig
The Pennsylvania Pharmacists Association (PPA) Board of Directors has named Victoria E. Elliott, RPh, MBA, CAE as Chief Executive Officer. Elliott will succeed Patricia A. Epple, CAE, who is retiring at the end of 2020.
“Pat has been an outstanding leader of PPA for the last almost two decades,” said Chuck Kray, president of PPA. “She is leaving a strong organization in the hands of an equally strong successor. We are looking forward to welcoming Victoria Elliott.” Epple has been with PPA since 2002.
As CEO, Elliott will blend her training as a registered pharmacist with her 24 years of experience in association management to lead PPA in its mission promoting the profession through advocacy, education, and communication to enhance patient care and public health. She will manage PPA operations, membership growth and engagement, and all program development and implementation. In addition, she will oversee PPA’s affiliated entities including its Educational Foundation, the Pennsylvania Pharmacists Care Network, and PharmPAC – PPA’s political action committee.
A Certified Association Executive since 2003, Elliott’s qualifications include alliance-building, volunteer engagement, board governance, leading legislative advocacy, and grassroots efforts to affect laws and regulations that critically impact healthcare professionals and the patients they serve. “I look forward to joining the PPA management team and am excited to work with my pharmacy colleagues and the PPA Board of Directors to advance the state of pharmacy practice across Pennsylvania,” said Elliott.
Prior to this appointment, Elliott was the CEO of the Association for the Advancement of Wound Care (AAWC), where she led a management transition, implementation of a three-year strategic plan, a branding campaign, and the launch of a series of educational summits focused on critical wound care issues. She also served as Executive Director for the American Neurological Association, Dermatology Nurses’ Association, Attention Deficit Disorder Association, and the Society For Biomaterials at Association Headquarters, and was the Executive Director for the Pennsylvania Society of Health-System Pharmacists from 1998 to 2005.
Before her career in association management, Elliott spent six years as a pediatric pharmacist in the Jefferson Health System, and two years as the Assistant Director of Pharmacy at Hahnemann University Hospital. In addition to her pharmacy degree from the Philadelphia College of Pharmacy, now part of the University of the Sciences, Elliott earned an MBA in Health and Medical Services from Widener University.
She is a Past President of the Mid-Atlantic Society of Association Executives (MASAE) and the Delaware Valley Society of Association Executives. She is also a member of the American Society of Association, the organization that confers the CAE designation. Elliott is a recipient of the MASAE Service Award for her distinguished service to the Association and in 2001, was recognized by the Philadelphia College of Pharmacy as the Young Alumnus Award winner.
Ms. Elliott will begin her new role on December 1, 2020. PSHP congratulates Ms. Elliott on this appointment and looks forward to working with her, and PPA, on Pennsylvania pharmacy issues.
Pennsylvania Society of Health System Pharmacists
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
30 min
December 08, 2020 Changing of the Guard | Beyond the Sig
The Pennsylvania Pharmacists Association (PPA) Board of Directors has named Victoria E. Elliott, RPh, MBA, CAE as Chief Executive Officer. Elliott will succeed Patricia A. Epple, CAE, who is retiring at the end of 2020.
“Pat has been an outstanding leader of PPA for the last almost two decades,” said Chuck Kray, president of PPA. “She is leaving a strong organization in the hands of an equally strong successor. We are looking forward to welcoming Victoria Elliott.” Epple has been with PPA since 2002.
As CEO, Elliott will blend her training as a registered pharmacist with her 24 years of experience in association management to lead PPA in its mission promoting the profession through advocacy, education, and communication to enhance patient care and public health. She will manage PPA operations, membership growth and engagement, and all program development and implementation. In addition, she will oversee PPA’s affiliated entities including its Educational Foundation, the Pennsylvania Pharmacists Care Network, and PharmPAC – PPA’s political action committee.
A Certified Association Executive since 2003, Elliott’s qualifications include alliance-building, volunteer engagement, board governance, leading legislative advocacy, and grassroots efforts to affect laws and regulations that critically impact healthcare professionals and the patients they serve. “I look forward to joining the PPA management team and am excited to work with my pharmacy colleagues and the PPA Board of Directors to advance the state of pharmacy practice across Pennsylvania,” said Elliott.
Prior to this appointment, Elliott was the CEO of the Association for the Advancement of Wound Care (AAWC), where she led a management transition, implementation of a three-year strategic plan, a branding campaign, and the launch of a series of educational summits focused on critical wound care issues. She also served as Executive Director for the American Neurological Association, Dermatology Nurses’ Association, Attention Deficit Disorder Association, and the Society For Biomaterials at Association Headquarters, and was the Executive Director for the Pennsylvania Society of Health-System Pharmacists from 1998 to 2005.
Before her career in association management, Elliott spent six years as a pediatric pharmacist in the Jefferson Health System, and two years as the Assistant Director of Pharmacy at Hahnemann University Hospital. In addition to her pharmacy degree from the Philadelphia College of Pharmacy, now part of the University of the Sciences, Elliott earned an MBA in Health and Medical Services from Widener University.
She is a Past President of the Mid-Atlantic Society of Association Executives (MASAE) and the Delaware Valley Society of Association Executives. She is also a member of the American Society of Association, the organization that confers the CAE designation. Elliott is a recipient of the MASAE Service Award for her distinguished service to the Association and in 2001, was recognized by the Philadelphia College of Pharmacy as the Young Alumnus Award winner.
Ms. Elliott will begin her new role on December 1, 2020. PSHP congratulates Ms. Elliott on this appointment and looks forward to working with her, and PPA, on Pennsylvania pharmacy issues.
Pennsylvania Society of Health System Pharmacists
See omnystudio.com/listener for privacy information.
30 min
December 07, 2020 The Importance of Medication Decision Support | First Data Bank
Everyone talks about clinical decision support—but what about ‘medication decision support’?
Clinical decision support (CDS) gets a lot of attention, but what about “medication decision support?” Increasingly, health system leaders are putting this issue front and center, especially as it relates to medication alerts that are integrated into EHR and clinician workflows. It’s important that medication alerts improve safety and quality while also making clinicians’ jobs easier. If not properly executed, these alerts can become a burden rather than a decision support tool.
In an interview, Anna Dover, PharmD, and Bob Katter can speak to best practices around medical decision support, including medication alerts:
Fit the medication decision support into the user’s workflow without interrupting them—and make the alerts actionable.
Move alerts to the time when they are relevant and to the best person capable of understanding and making a decision about the risk/medication.
Use decision support that incorporates patient characteristics. We are going to see that alerts and decision support that rely only on medication lists and nothing more specific from the patient will start to fade away. That traditional approach, although very sensitive, is not very specific. In other words, the alert was good at telling you about a potential risk, but not good about telling you whether this specific patient was at higher or lower risk.
We know have the technical capability to leverage lab results, patient age, gender, diagnosis, and other factors to fire an alert when the risk is high—or automatically suppress an alert when the risk is low.
Leverage analytics for better medication decision support. By looking at the data being generated through prescribing, we can make predictions about how a clinician or set of clinicians will respond to alert-tuning or modification.
It’s possible to simulate and make educated guesses about whether an alert will have the intended effect and improve care, or whether it will cause additional burden to the prescriber.
Medication decision support can also go a step further: This data can be leveraged to make specific predictions about a patient, such as quantifying their risk of opioid addiction—or even better, their risk of facing a whole host of adverse drug events.
That determination may be based upon their genetics, co-morbidities, and current physical state.
The future of medication decision support will focus on a combination of curated, evidence-based rules/knowledge and AI-driven pattern recognition.
When we have better alerts, we can use analytics to prove that they work better; they can be installed side-by-side with traditional alerts to validate that an advanced system is safe and effective—ultimately enabling the removal of traditional alerts.
Monitor the impact of deployments, get feedback, and respond, in order to optimize. It’s important to closely manage and maintain your knowledge system to reflect evidence and pivot as needed.
First Databank (FDB) is the largest drug database in the United States. Bob and Anna are in discussions with health systems, hospitals, and community and retail pharmacists on a daily basis and have in depth knowledge on pain points and opportunities related to the pharmacy industry across the healthcare landscape. Anna from a Pharm D’s perspective and Bob from a business leadership perspective.
Guests:
Anna Dover, PharmD, Director, Product Management, (FDB)
LinkedIn profile: https://www.linkedin.com/in/anna-dover-02137117/
Bob Katter, President of First Databank (FDB)
Bio on FDB website: https://www.fdbhealth.com/company/leadership/bob-katter
LinkedIn profile: https://www.linkedin.com/in/bobkatter/
This episode was sponsored by First Databank
See omnystudio.com/listener for privacy information.
33 min
December 07, 2020 The Importance of Medication Decision Support | First Data Bank
Everyone talks about clinical decision support—but what about ‘medication decision support’?
Clinical decision support (CDS) gets a lot of attention, but what about “medication decision support?” Increasingly, health system leaders are putting this issue front and center, especially as it relates to medication alerts that are integrated into EHR and clinician workflows. It’s important that medication alerts improve safety and quality while also making clinicians’ jobs easier. If not properly executed, these alerts can become a burden rather than a decision support tool.
In an interview, Anna Dover, PharmD, and Bob Katter can speak to best practices around medical decision support, including medication alerts:
Fit the medication decision support into the user’s workflow without interrupting them—and make the alerts actionable.
Move alerts to the time when they are relevant and to the best person capable of understanding and making a decision about the risk/medication.
Use decision support that incorporates patient characteristics. We are going to see that alerts and decision support that rely only on medication lists and nothing more specific from the patient will start to fade away. That traditional approach, although very sensitive, is not very specific. In other words, the alert was good at telling you about a potential risk, but not good about telling you whether this specific patient was at higher or lower risk.
We know have the technical capability to leverage lab results, patient age, gender, diagnosis, and other factors to fire an alert when the risk is high—or automatically suppress an alert when the risk is low.
Leverage analytics for better medication decision support. By looking at the data being generated through prescribing, we can make predictions about how a clinician or set of clinicians will respond to alert-tuning or modification.
It’s possible to simulate and make educated guesses about whether an alert will have the intended effect and improve care, or whether it will cause additional burden to the prescriber.
Medication decision support can also go a step further: This data can be leveraged to make specific predictions about a patient, such as quantifying their risk of opioid addiction—or even better, their risk of facing a whole host of adverse drug events.
That determination may be based upon their genetics, co-morbidities, and current physical state.
The future of medication decision support will focus on a combination of curated, evidence-based rules/knowledge and AI-driven pattern recognition.
When we have better alerts, we can use analytics to prove that they work better; they can be installed side-by-side with traditional alerts to validate that an advanced system is safe and effective—ultimately enabling the removal of traditional alerts.
Monitor the impact of deployments, get feedback, and respond, in order to optimize. It’s important to closely manage and maintain your knowledge system to reflect evidence and pivot as needed.
First Databank (FDB) is the largest drug database in the United States. Bob and Anna are in discussions with health systems, hospitals, and community and retail pharmacists on a daily basis and have in depth knowledge on pain points and opportunities related to the pharmacy industry across the healthcare landscape. Anna from a Pharm D’s perspective and Bob from a business leadership perspective.
Guests:
Anna Dover, PharmD, Director, Product Management, (FDB)
LinkedIn profile: https://www.linkedin.com/in/anna-dover-02137117/
Bob Katter, President of First Databank (FDB)
Bio on FDB website: https://www.fdbhealth.com/company/leadership/bob-katter
LinkedIn profile: https://www.linkedin.com/in/bobkatter/
This episode was sponsored by First Databank
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
33 min
December 04, 2020 Community Pharmacy Practice: Looking Back and Looking Forward | Beyond the Sig
In this episode of Beyond the Sig, Brooke Kulusich, a third-year student pharmacist at the University of Pittsburgh School of Pharmacy, sits down with Melissa S. McGivney, PharmD, FCCP, FAPhA who serves as Associate Dean for Community Partnerships and Professor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. As a national leader in advancing pharmacist-provided patient care in the community for 20 years, Dr. McGivney shares her perspective on the progress our profession has made and the challenges that lie ahead.
See omnystudio.com/listener for privacy information.
26 min
December 04, 2020 Community Pharmacy Practice: Looking Back and Looking Forward | Beyond the Sig
In this episode of Beyond the Sig, Brooke Kulusich, a third-year student pharmacist at the University of Pittsburgh School of Pharmacy, sits down with Melissa S. McGivney, PharmD, FCCP, FAPhA who serves as Associate Dean for Community Partnerships and Professor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. As a national leader in advancing pharmacist-provided patient care in the community for 20 years, Dr. McGivney shares her perspective on the progress our profession has made and the challenges that lie ahead.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
26 min
December 04, 2020 Medication Adherence During The COVID-19 Pandemic | PsychU Community Podcast
Medication adherence has proven challenging for many individuals during the coronavirus pandemic. For all the convenience offered by virtual visits, they make it more difficult to administer injections or assess how patients are responding to medication. Difficulty obtaining refills or necessary lab work can be barriers to medication adherence, as well. Care coordination is especially important now, says Dr. Ehret, who also suggests that providers consider giving patients extra refills when warranted—and check in on patients most at risk for medication nonadherence.
Featuring:
Megan Ehret, PharmD, MS, BCPP
Associate Professor at the University of Maryland School of Pharmacy and PsychU Pharmacist Corner Advisor
Joseph Cirrincione, PharmD, MBA
Medical Science Liaison, Otsuka Pharmaceutical Development & Commercialization, Inc.
Megan Ehret, PharmD, MS, BCPP, is Associate Professor in the Department of Pharmacy Practice & Science at the University of Maryland School of Pharmacy. A board-certified psychiatric pharmacist, she is also PsychU’s Pharmacist Corner Section Advisor.
Joseph Cirrincione, PharmD, MBA, is Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc.
Speakers are paid consultants or employees of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community.
The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis.
Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional.
No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
12 min

About Pharmacy Podcast Network

From the publisher's feed

Pharmacy Podcast Network (PPN) is the world’s largest network of podcasts dedicated to the pharmacy professional and industry insiders. Our content is about dynamic people in the pharmacy industry making a difference and delivering the best pharmacy care. We have over 40+ podcasts with thousands of interviews.

Pharmacists are the cornerstone of healthcare, and the PPN reflects that. From Community, LTC, Specialty Pharmacy to Drug Development, Government policy and DigitalHealth, we cover it all. Partner with us to connect with thousands of daily listeners and find the right pharmacist across various specialties and topics, ensuring your products and services resonate where it matters most. We build strong audio brands through Pharmacists who see patients almost 9x more than primary care.